CD19 and acute lymphoblastic leukemia: The results presented in our study indicate that CD19 CAR T cells derived from hybridoma clone HI19α (HI19α-4-1BB-ζ CAR T) are highly effective against malignant cells in patients diagnosed with R/R B-ALL.